Identification of a simple chemical structure associated with protective human antibodies against multiple pneumococcal serogroups

Infection and Immunity

Volumn 77, Issue 8, 2009, Pages 3374-3379

  Park, Saeyoung ^a   Parameswar, Archana R ^b   Demchenko, Alexei V ^b   Nahm, Moon H ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF MISSOURI ST LOUIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISERUM; BACTERIAL POLYSACCHARIDE; CARBOHYDRATE; EPITOPE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY DOB1; UNCLASSIFIED DRUG;

ANTIGEN BINDING; ANTIGEN RECOGNITION; ARTICLE; BACTERIAL MEMBRANE; BLOOD GROUP TYPING; CHEMICAL STRUCTURE; CONTROLLED STUDY; CROSS REACTION; HUMAN; HUMAN EXPERIMENT; OPSONIZATION; PRIORITY JOURNAL; SEROTYPING; STREPTOCOCCUS PNEUMONIAE;

AGED; AGED, 80 AND OVER; ANTIBODIES, BACTERIAL; BACTERIAL CAPSULES; CARBOHYDRATE SEQUENCE; CROSS REACTIONS; EPITOPES; HUMANS; MIDDLE AGED; MOLECULAR SEQUENCE DATA; OPSONIN PROTEINS; PNEUMOCOCCAL INFECTIONS; SEROTYPING; STREPTOCOCCUS PNEUMONIAE;

EID: 67651225311     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00319-09     Document Type: Article

References (33)

1. Alonso de Velasco, E., A. F. Verheul, A. M. van Steijn, H. A. Dekker, R. G. Feldman, I. M. Fernandez, J. P. Kamerling, J. F. Vliegenthart, J. Verhoef, and H. Snippe. 1994. Epitope specificity of rabbit immunoglobulin G (IgG) elicited by pneumococcal type 23F synthetic oligosaccharide- and native polysaccharide-protein conjugate vaccines: comparison with human antipolysaccharide 23F IgG. Infect. Immun. 62:799-808.
2. Baxendale, H. E., M. Johnson, R. C. Stephens, J. Yuste, N. Klein, J. S. Brown, and D. Goldblatt. 2008. Natural human antibodies to pneumococcus have distinctive molecular characteristics and protect against pneumococcal disease. Clin. Exp. Immunol. 151:51-60.
3. Benaissa-Trouw, B., D. J. Lefeber, J. P. Kamerling, J. F. Vliegenthart, K. Kraaijeveld, and H. Snippe. 2001. Synthetic polysaccharide type 3-related di-, tri-, and tetrasaccharide-CRM(197) conjugates induce protection against Streptococcus pneumoniae type 3 in mice. Infect. Immun. 69:4698-4701.
4. Burton, R. L., and M. H. Nahm. 2006. Development and validation of a fourfold multiplexed opsonization assay (MOPA4) for pneumococcal antibodies. Clin. Vaccine Immunol. 13:1004-1009.
5. Fedson, D. S., and D. M. Musher. 1994. Pneumococcal vaccine, p. 517-564. In S. A. Plotkin and E. A. Mortimer (ed.), Vaccines, 2nd ed. The W. B. Saunders Co., Philadelphia, PA.
6. Heidelberger, M., and P. A. Rebers. 1960. Immunochemistry of the pneumococcal types II, V, and VI: the relation of type VI to type II and other correlations between chemical constitution and precipitation in antisera to type VI. J. Bacteriol. 80:145-153.
7. Heidelberger, M., and J. M. Tyler. 1964. Cross-reactions of pneumococcal types. J. Exp. Med. 120:711-719.
8. Henrichsen, J. 1995. Six newly recognized types of Streptococcus pneumoniae. J. Clin. Microbiol. 33:2759-2762.
9. Hicks, L. A., L. H. Harrison, B. Flannery, J. L. Hadler, W. Schaffner, A. S. Craig, D. Jackson, A. Thomas, B. Beall, R. Lynfield, A. Reingold, M. M. Farley, and C. G. Whitney. 2007. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J. Infect. Dis. 196:1346-1354.
10. Insel, R. A., A. Kittelberger, and P. Anderson. 1985. Isoelectric focusing of human antibody to the Haemophilus influenzae b capsular polysaccharide: restricted and identical spectrotypes in adults. J. Immunol. 135:2810-2816.
11. Jansen, W. T., S. Hogenboom, M. J. Thijssen, J. P. Kamerling, J. F. Vliegenthart, J. Verhoef, H. Snippe, and A. F. Verheul. 2001. Synthetic 6B di-, tri-, and tetrasaccharide-protein conjugates contain pneumococcal type 6A and 6B common and 6B-specific epitopes that elicit protective antibodies in mice. Infect. Immun. 69:787-793.
12. Jansen, W. T., and H. Snippe. 2004. Short-chain oligosaccharide protein conjugates as experimental pneumococcal vaccines. Indian J. Med. Res. 119(Suppl.):7-12.
13. Jansen, W. T., A. F. Verheul, G. H. Veeneman, J. H. van Boom, and H. Snippe. 2001. Revised interpretation of the immunological results obtained with pneumococcal polysaccharide 17F derived synthetic di-, tri-, and tetrasaccharide conjugates in mice and rabbits. Vaccine 20:19-21.
14. Kamerling, J. P. 2000. Pneumococcal polysaccharides: a chemical view, p. 81-114. In A. Tomasz (ed.), Streptococcus pneumoniae molecular biology and mechanisms of disease. Mary Ann Liebert, Inc., New Rochelle, NY.
15. Kauffmann, F., E. Morch, and K. Schmith. 1940. On the serology of the pneumococcus group. J. Immunol. 39:397-426.
16. Mahjoub-Messai, F., C. Doit, J. L. Koeck, T. Billard, B. Evrard, P. Bidet, C. Hubans, J. Raymond, C. Levy, R. Cohen, and E. Bingen. 2009. Population snapshot of Streptococcus pneumoniae serotype 19A isolates before and after introduction of seven-valent pneumococcal vaccination for French children. J. Clin. Microbiol. 47:837-840.
17. Moore, M. R., R. E. Gertz, Jr., R. L. Woodbury, G. A. Barkocy-Gallagher, W. Schaffner, C. Lexau, K. Gershman, A. Reingold, M. Farley, L. H. Harrison, J. L. Hadler, N. M. Bennett, A. R. Thomas, L. McGee, T. Pilishvili, A. B. Brueggemann, C. G. Whitney, J. H. Jorgensen, and B. Beall. 2008. Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005. J. Infect. Dis. 197:1016-1027.
18. Nahm, M. H., J. Lin, J. A. Finkelstein, and S. I. Pelton. 2009. Increase in the prevalence of the newly discovered pneumococcal serotype 6C in the nasopharynx after introduction of pneumococcal conjugate vaccine. J. Infect. Dis. 199:320-325.
19. Parameswar, A. R., S. J. Hasty, and A. V. Demchenko. 2008. Synthesis of spacer-containing analogs of serogroup 6 pneumococcal oligosaccharides. Carbohydr. Res. 343:1707-1717.
20. Parameswar, A. R., P. Pornsuriyasak, N. A. Lubanowski, and A. V. Demchenko. 2007. Efficient stereoselective synthesis of oligosaccharides of Streptococcus pneumoniae serotypes 6A and 6B containing multiple 1,2-cis glycosidic linkages. Tetrahedron 63:10083-10091.
21. Park, I. H., M. R. Moore, J. J. Treanor, S. I. Pelton, T. Pilishvili, B. Beall, M. A. Shelly, B. E. Mahon, and M. H. Nahm. 2008. Differential effects of pneumococcal vaccines against serotypes 6A and 6C. J. Infect. Dis. 198: 1818-1822.
22. Park, I. H., D. G. Pritchard, R. Cartee, A. Brandao, M. C. Brandileone, and M. H. Nahm. 2007. Discovery of a new capsular serotype (6C) within serogroup 6 of Streptococcus pneumoniae. J. Clin. Microbiol. 45:1225-1233.
23. Prymula, R., P. Peeters, V. Chrobok, P. Kriz, E. Novakova, E. Kaliskova, I. Kohl, P. Lommel, J. Poolman, J. P. Prieels, and L. Schuerman. 2006. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet 367:740-748.
24. Rennels, M. B., K. M. Edwards, H. L. Keyserling, K. S. Reisinger, D. A. Hogerman, D. V. Madore, I. Chang, P. R. Paradiso, F. J. Malinoski, and A. Kimura. 1998. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants. Pediatrics 101:604-611.
25. Robbins, J. B., R. Austrian, C. J. Lee, S. C. Rastogi, G. Schiffman, J. Henrichsen, P. H. Makela, C. V. Broome, R. R. Facklam, R. H. Tiesjema, and J. C. Parke, Jr. 1983. Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the crossreactive types within groups. J. Infect. Dis. 148:1136-1159.
26. Saeland, E., G. Vidarsson, J. H. Leusen, E. Van Garderen, M. H. Nahm, H. Vile-Weekhout, V. Walraven, A. M. Stemerding, J. S. Verbeek, G. T. Rijkers, W. Kuis, E. A. Sanders, and J. G. Van De Winkel. 2003. Central role of complement in passive protection by human IgG1 and IgG2 anti-pneumococcal antibodies in mice. J. Immunol. 170:6158-6164.
27. Safari, D., H. A. Dekker, J. A. Joosten, D. Michalik, A. C. de Souza, R. Adamo, M. Lahmann, A. Sundgren, S. Oscarson, J. P. Kamerling, and H. Snippe. 2008. Identification of the smallest structure capable of evoking opsonophagocytic antibodies against Streptococcus pneumoniae type 14. Infect. Immun. 76:4615-4623.
28. Scott, M. G., D. L. Crimmins, D. W. McCourt, I. Zocher, R. Thiebe, H. G. Zachau, and M. H. Nahm. 1989. Clonal characterization of the human IgG antibody repertoire to Haemophilus influenzae type b polysaccharide. III. A single VKII gene and one of several JK genes are joined by an invariant arginine to form the most common L chain V region. J. Immunol. 143:4110-4116.
29. Song, J. H., J. Y. Baek, H. S. Cheong, D. R. Chung, K. R. Peck, and H. L. Ko. 2009. Changes of serotype and genotype in Streptococcus pneumoniae isolates from a Korean hospital in 2007. Diagn. Microbiol. Infect. Dis. 63:271-278.
30. Sun, Y., M. K. Park, J. Kim, B. Diamond, A. Solomon, and M. H. Nahm. 1999. Repertoire of human antibodies against the polysaccharide capsule of Streptococcus pneumoniae serotype 6B. Infect. Immun. 67:1172-1179.
31. Vakevainen, M., C. Eklund, J. Eskola, and H. Kayhty. 2001. Cross-reactivity of antibodies to type 6B and 6A polysaccharides of Streptococcus pneumoniae, evoked by pneumococcal conjugate vaccines, in infants. J. Infect. Dis. 184:789-793.
32. Verez-Bencomo, V., V. Fernandez-Santana, E. Hardy, M. E. Toledo, M. C. Rodriguez, L. Heynngnezz, A. Rodriguez, A. Baly, L. Herrera, M. Izquierdo, A. Villar, Y. Valdes, K. Cosme, M. L. Deler, M. Montane, E. Garcia, A. Ramos, A. Aguilar, E. Medina, G. Torano, I. Sosa, I. Hernandez, R. Martinez, A. Muzachio, A. Carmenates, L. Costa, F. Cardoso, C. Campa, M. Diaz, and R. Roy. 2004. A synthetic conjugate polysaccharide vaccine against Haemophilus influenzae type b. Science 305:522-525.
33. Whitney, C. G., M. M. Farley, J. Hadler, L. H. Harrison, N. M. Bennett, R. Lynfield, A. Reingold, P. R. Cieslak, T. Pilishvili, D. Jackson, R. R. Facklam, J. H. Jorgensen, and A. Schuchat. 2003. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N. Engl. J. Med. 348:1737-1746.